JP2013512215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512215A5 JP2013512215A5 JP2012540402A JP2012540402A JP2013512215A5 JP 2013512215 A5 JP2013512215 A5 JP 2013512215A5 JP 2012540402 A JP2012540402 A JP 2012540402A JP 2012540402 A JP2012540402 A JP 2012540402A JP 2013512215 A5 JP2013512215 A5 JP 2013512215A5
- Authority
- JP
- Japan
- Prior art keywords
- chroman
- pyrrolo
- amino
- pyrimidin
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 hydroxy, amino Chemical group 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000003003 spiro group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 1
- XRVHJTJZLIVDQA-UHFFFAOYSA-N 1-[[3-[4-amino-5-(2-phenyl-3,4-dihydro-2h-chromen-7-yl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl]methyl]piperidin-4-ol Chemical compound C1=2C(N)=NC=NC=2N(C2CC(CN3CCC(O)CC3)C2)C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=C1 XRVHJTJZLIVDQA-UHFFFAOYSA-N 0.000 claims 1
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 claims 1
- IHXVQVHYGOMGDE-UHFFFAOYSA-N 4-[[3-[4-amino-5-(2-phenyl-3,4-dihydro-2h-chromen-7-yl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl]methyl]-1-methylpiperazin-2-one Chemical compound C1C(=O)N(C)CCN1CC1CC(N2C3=NC=NC(N)=C3C(C=3C=C4OC(CCC4=CC=3)C=3C=CC=CC=3)=C2)C1 IHXVQVHYGOMGDE-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- PHVIIBUNLRRJSZ-BEDZIMQSSA-N C([C@H]1C[C@H](C1)N1C=C(C2=C(N)N=CN=C21)C1=CC=C2CCC(OC2=C1)COCC)N1CCS(=O)CC1 Chemical compound C([C@H]1C[C@H](C1)N1C=C(C2=C(N)N=CN=C21)C1=CC=C2CCC(OC2=C1)COCC)N1CCS(=O)CC1 PHVIIBUNLRRJSZ-BEDZIMQSSA-N 0.000 claims 1
- BNNWRUYZDOLKJC-AQKFKSFVSA-N C1([C@@H]2CCC3=CC=C(C=C3O2)C2=CN(C=3N=CN=C(C2=3)N)[C@H]2C[C@@H](CO)C2)=CC=CC=C1 Chemical compound C1([C@@H]2CCC3=CC=C(C=C3O2)C2=CN(C=3N=CN=C(C2=3)N)[C@H]2C[C@@H](CO)C2)=CC=CC=C1 BNNWRUYZDOLKJC-AQKFKSFVSA-N 0.000 claims 1
- RSBQTLSGSPBIIE-NNKBHPLTSA-N C1([C@H]2CCC3=CC=C(C=C3O2)C2=CN(C=3N=CN=C(C2=3)N)[C@H]2C[C@@H](CN3[C@@H](CCC3)CO)C2)=CC=CC=C1 Chemical compound C1([C@H]2CCC3=CC=C(C=C3O2)C2=CN(C=3N=CN=C(C2=3)N)[C@H]2C[C@@H](CN3[C@@H](CCC3)CO)C2)=CC=CC=C1 RSBQTLSGSPBIIE-NNKBHPLTSA-N 0.000 claims 1
- BNNWRUYZDOLKJC-QGCDCVKKSA-N C1([C@H]2CCC3=CC=C(C=C3O2)C2=CN(C=3N=CN=C(C2=3)N)[C@H]2C[C@@H](CO)C2)=CC=CC=C1 Chemical compound C1([C@H]2CCC3=CC=C(C=C3O2)C2=CN(C=3N=CN=C(C2=3)N)[C@H]2C[C@@H](CO)C2)=CC=CC=C1 BNNWRUYZDOLKJC-QGCDCVKKSA-N 0.000 claims 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims 1
- QZSDGBOGOGOEHX-KQYMJHLBSA-N C12=C(N)N=CN=C2N([C@@H]2C[C@@H](C2)CN2C[C@@]3(C[C@]2(CS3(=O)=O)[H])[H])C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=N1 Chemical compound C12=C(N)N=CN=C2N([C@@H]2C[C@@H](C2)CN2C[C@@]3(C[C@]2(CS3(=O)=O)[H])[H])C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=N1 QZSDGBOGOGOEHX-KQYMJHLBSA-N 0.000 claims 1
- WGBJMKBGDNBCMU-MAOIWGCQSA-N C1=2C(N)=NC=NC=2N([C@H]2CC[C@H](CC2)NC(=O)C2CC2)C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=C1 Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CC[C@H](CC2)NC(=O)C2CC2)C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=C1 WGBJMKBGDNBCMU-MAOIWGCQSA-N 0.000 claims 1
- PXXZPGFGDTVGOE-RZJSWYKGSA-N C1=2C(N)=NC=NC=2N([C@H]2C[C@@H](CN3CCS(=O)(=O)CC3)C2)C=C1C(C=C1O2)=CC=C1CC=C2C1=CC=CC=C1 Chemical compound C1=2C(N)=NC=NC=2N([C@H]2C[C@@H](CN3CCS(=O)(=O)CC3)C2)C=C1C(C=C1O2)=CC=C1CC=C2C1=CC=CC=C1 PXXZPGFGDTVGOE-RZJSWYKGSA-N 0.000 claims 1
- NSUWQVFRRVVGTH-UHGJSFDGSA-N C1=2C(N)=NC=NC=2N([C@H]2C[C@@H](CN3CCS(=O)(=O)CC3)C2)C=C1C(C=C1O2)=CC=C1CCC12CCCCC1 Chemical compound C1=2C(N)=NC=NC=2N([C@H]2C[C@@H](CN3CCS(=O)(=O)CC3)C2)C=C1C(C=C1O2)=CC=C1CCC12CCCCC1 NSUWQVFRRVVGTH-UHGJSFDGSA-N 0.000 claims 1
- UKIFTTIWWVAGHO-NSWDLBSPSA-N C1=2C(N)=NC=NC=2N([C@H]2C[C@@H](CN3CCS(=O)(=O)CC3)C2)C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=N1 Chemical compound C1=2C(N)=NC=NC=2N([C@H]2C[C@@H](CN3CCS(=O)(=O)CC3)C2)C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=N1 UKIFTTIWWVAGHO-NSWDLBSPSA-N 0.000 claims 1
- ZOPMETKNELTEBW-NSWDLBSPSA-N C1=2C(N)=NC=NC=2N([C@H]2C[C@@H](CN3CCS(=O)CC3)C2)C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=N1 Chemical compound C1=2C(N)=NC=NC=2N([C@H]2C[C@@H](CN3CCS(=O)CC3)C2)C=C1C(C=C1O2)=CC=C1CCC2C1=CC=CC=N1 ZOPMETKNELTEBW-NSWDLBSPSA-N 0.000 claims 1
- WNKDWFNWCAHYJJ-NSWDLBSPSA-N C1C(=O)N(C)CCN1C[C@@H]1C[C@H](N2C3=NC=NC(N)=C3C(C=3C=C4OC(CCC4=CC=3)C=3N=CC=CC=3)=C2)C1 Chemical compound C1C(=O)N(C)CCN1C[C@@H]1C[C@H](N2C3=NC=NC(N)=C3C(C=3C=C4OC(CCC4=CC=3)C=3N=CC=CC=3)=C2)C1 WNKDWFNWCAHYJJ-NSWDLBSPSA-N 0.000 claims 1
- UFCGRTAECNYGTK-YHQISMHQSA-N C1C(=O)N(C)CCN1[C@@H]1CC[C@H](N2C3=NC=NC(N)=C3C(C=3C=C4OC(CCC4=CC=3)C=3C=CC=CC=3)=C2)CC1 Chemical compound C1C(=O)N(C)CCN1[C@@H]1CC[C@H](N2C3=NC=NC(N)=C3C(C=3C=C4OC(CCC4=CC=3)C=3C=CC=CC=3)=C2)CC1 UFCGRTAECNYGTK-YHQISMHQSA-N 0.000 claims 1
- LEPZORHVXIZEEV-MAOIWGCQSA-N C1C[C@@H](NC(=O)C(C)C)CC[C@H]1N1C2=NC=NC(N)=C2C(C=2C=C3OC(CCC3=CC=2)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](NC(=O)C(C)C)CC[C@H]1N1C2=NC=NC(N)=C2C(C=2C=C3OC(CCC3=CC=2)C=2C=CC=CC=2)=C1 LEPZORHVXIZEEV-MAOIWGCQSA-N 0.000 claims 1
- ITBXFQFOWLZLON-HCGNOCCLSA-N C1C[C@@H](NC(=O)C)CC[C@H]1N1C2=NC=NC(N)=C2C(C=2C=C3OC(CCC3=CC=2)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](NC(=O)C)CC[C@H]1N1C2=NC=NC(N)=C2C(C=2C=C3OC(CCC3=CC=2)C=2C=CC=CC=2)=C1 ITBXFQFOWLZLON-HCGNOCCLSA-N 0.000 claims 1
- UFHSIIUDAJRVOQ-JQUQNNEZSA-N C1[C@@H](CNC(=O)C)C[C@H]1N1C2=NC=NC(N)=C2C(C=2C=C3OC(CCC3=CC=2)C=2N=CC=CC=2)=C1 Chemical compound C1[C@@H](CNC(=O)C)C[C@H]1N1C2=NC=NC(N)=C2C(C=2C=C3OC(CCC3=CC=2)C=2N=CC=CC=2)=C1 UFHSIIUDAJRVOQ-JQUQNNEZSA-N 0.000 claims 1
- NAFUXRLPEGOBPU-FGZXBEKLSA-N C=12C(N)=NC=CN2C([C@H]2C[C@@H](CN3C(=NC=C3)CO)C2)=NC=1C(C=C1O2)=CC=C1CCC2C1=CC=CC=C1 Chemical compound C=12C(N)=NC=CN2C([C@H]2C[C@@H](CN3C(=NC=C3)CO)C2)=NC=1C(C=C1O2)=CC=C1CCC2C1=CC=CC=C1 NAFUXRLPEGOBPU-FGZXBEKLSA-N 0.000 claims 1
- YEVAYMGEDSOBMB-SDKMGWRVSA-N CC1=NN=NN1C[C@@H]1C[C@H](N2C3=NC=NC(N)=C3C(C=3C=C4OC(CCC4=CC=3)C=3C=CC=CC=3)=C2)C1 Chemical compound CC1=NN=NN1C[C@@H]1C[C@H](N2C3=NC=NC(N)=C3C(C=3C=C4OC(CCC4=CC=3)C=3C=CC=CC=3)=C2)C1 YEVAYMGEDSOBMB-SDKMGWRVSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- DBZXVGWMVCAJQO-CTZQYXLCSA-N NC(=O)[C@@H]1CCCN1C[C@@H]1C[C@H](C=2N3C=CN=C(N)C3=C(C=3C=C4O[C@@H](CCC4=CC=3)C=3C=CC=CC=3)N=2)C1 Chemical compound NC(=O)[C@@H]1CCCN1C[C@@H]1C[C@H](C=2N3C=CN=C(N)C3=C(C=3C=C4O[C@@H](CCC4=CC=3)C=3C=CC=CC=3)N=2)C1 DBZXVGWMVCAJQO-CTZQYXLCSA-N 0.000 claims 1
- DBZXVGWMVCAJQO-ZZQRAECTSA-N NC(=O)[C@@H]1CCCN1C[C@@H]1C[C@H](C=2N3C=CN=C(N)C3=C(C=3C=C4O[C@H](CCC4=CC=3)C=3C=CC=CC=3)N=2)C1 Chemical compound NC(=O)[C@@H]1CCCN1C[C@@H]1C[C@H](C=2N3C=CN=C(N)C3=C(C=3C=C4O[C@H](CCC4=CC=3)C=3C=CC=CC=3)N=2)C1 DBZXVGWMVCAJQO-ZZQRAECTSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26448209P | 2009-11-25 | 2009-11-25 | |
| US61/264,482 | 2009-11-25 | ||
| PCT/EP2010/068038 WO2011064211A1 (en) | 2009-11-25 | 2010-11-23 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013512215A JP2013512215A (ja) | 2013-04-11 |
| JP2013512215A5 true JP2013512215A5 (https=) | 2014-01-16 |
Family
ID=43416523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540402A Pending JP2013512215A (ja) | 2009-11-25 | 2010-11-23 | 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120289501A1 (https=) |
| EP (1) | EP2504339A1 (https=) |
| JP (1) | JP2013512215A (https=) |
| CN (1) | CN102712648A (https=) |
| WO (1) | WO2011064211A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5985658B2 (ja) * | 2012-01-31 | 2016-09-06 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | ブルトンチロシンキナーゼ阻害薬としての環状分子 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| TW225528B (https=) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| BR9207175A (pt) | 1992-10-28 | 1995-12-12 | Genentech Inc | Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero |
| JP4145955B2 (ja) | 1994-09-29 | 2008-09-03 | ノバルティス アクチェンゲゼルシャフト | ピロロ〔２，３−ｄ〕ピリミジン及びその使用 |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| GB9517060D0 (en) | 1995-08-17 | 1995-10-25 | Ciba Geigy Ag | Acylated oligopeptide derivatives |
| GB9516842D0 (en) | 1995-08-17 | 1995-10-18 | Ciba Geigy Ag | Various acylated oligopeptides |
| DE19533099A1 (de) | 1995-09-07 | 1997-03-13 | Siemens Nixdorf Inf Syst | Betriebszustandsanzeige |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US7863444B2 (en) * | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| CA2344262A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | 4-aminopyrrolopyrimidines as kinase inhibitors |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| WO2000037502A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| WO2000059509A1 (en) | 1999-03-30 | 2000-10-12 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| PT1254138E (pt) | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| AR035885A1 (es) * | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| TWI378934B (en) | 2004-04-02 | 2012-12-11 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| WO2006113483A2 (en) * | 2005-04-15 | 2006-10-26 | Schering Corporation | Methods and compositions for treating or preventing cancer |
| TW200730529A (en) | 2005-12-07 | 2007-08-16 | Osi Pharm Inc | Process to prepare substituted imidazopyrazine compounds |
| JP2009520028A (ja) * | 2005-12-19 | 2009-05-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Ｉｇｆｒ抑制剤および抗癌剤の併用 |
| TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
| DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| CA2672828A1 (en) * | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of treatment |
| WO2008109057A1 (en) * | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
| EP2178563A2 (en) | 2007-07-06 | 2010-04-28 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2 |
| EP2238134A2 (en) | 2007-12-20 | 2010-10-13 | Novartis AG | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
| EP2240475B1 (en) | 2007-12-20 | 2013-09-25 | Novartis AG | Thiazole derivatives used as pi 3 kinase inhibitors |
-
2010
- 2010-11-23 WO PCT/EP2010/068038 patent/WO2011064211A1/en not_active Ceased
- 2010-11-23 JP JP2012540402A patent/JP2013512215A/ja active Pending
- 2010-11-23 CN CN2010800622194A patent/CN102712648A/zh active Pending
- 2010-11-23 US US13/511,564 patent/US20120289501A1/en not_active Abandoned
- 2010-11-23 EP EP10779562A patent/EP2504339A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024532733A (ja) | 複素環式化合物及び使用方法 | |
| IL292229A (en) | Pharmacological combination of prmt5 inhibitors | |
| JP2004533454A5 (https=) | ||
| RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
| EP4237086A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2025508702A (ja) | キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用 | |
| JP2007534687A5 (https=) | ||
| JP2021525783A5 (https=) | ||
| JP2016537384A5 (https=) | ||
| IL276865A (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor | |
| JP2012501312A5 (https=) | ||
| FI3436461T3 (fi) | Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina | |
| ZA201808534B (en) | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide | |
| RU2017121278A (ru) | Триазоло-пиразинильные производные, применимые в качестве растворимых активаторов гуанилатциклазы | |
| CA2677572A1 (en) | 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors | |
| JP2015517566A5 (https=) | ||
| JP2011500774A5 (https=) | ||
| JP2013523884A5 (https=) | ||
| CN112204027A (zh) | Erk 抑制剂及其应用 | |
| SI3083625T1 (en) | Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors | |
| JP2009507758A5 (https=) | ||
| JP2011511034A5 (https=) | ||
| RU2017141077A (ru) | Ингибитор некоторых протеинкиназ | |
| JP2003531210A5 (https=) | ||
| ME02906B (me) | Derivati pirazolopirolidina i njihova upotreba u liječenju bolesti |